HK1219233A1 - 美罗培南衍生物及其用途 - Google Patents

美罗培南衍生物及其用途 Download PDF

Info

Publication number
HK1219233A1
HK1219233A1 HK16107322.6A HK16107322A HK1219233A1 HK 1219233 A1 HK1219233 A1 HK 1219233A1 HK 16107322 A HK16107322 A HK 16107322A HK 1219233 A1 HK1219233 A1 HK 1219233A1
Authority
HK
Hong Kong
Prior art keywords
particles
pharmaceutical compositions
inventive
meropenem
respiratory tract
Prior art date
Application number
HK16107322.6A
Other languages
English (en)
Chinese (zh)
Inventor
Winston Zapanta ONG
Pawel Wojciech Nowak
Jinsoo Kim
Elizabeth M. Enlow
James BOURASSA
Yen CU
Alexey Popov
Hongming Chen
Original Assignee
Kala Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kala Pharmaceuticals, Inc. filed Critical Kala Pharmaceuticals, Inc.
Publication of HK1219233A1 publication Critical patent/HK1219233A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16107322.6A 2013-03-15 2014-03-14 美罗培南衍生物及其用途 HK1219233A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789335P 2013-03-15 2013-03-15
US61/789,335 2013-03-15
PCT/US2014/028627 WO2014144285A1 (en) 2013-03-15 2014-03-14 Meropenem derivatives and uses thereof

Publications (1)

Publication Number Publication Date
HK1219233A1 true HK1219233A1 (zh) 2017-03-31

Family

ID=51537664

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16107322.6A HK1219233A1 (zh) 2013-03-15 2014-03-14 美罗培南衍生物及其用途

Country Status (8)

Country Link
US (4) US9725451B2 (cg-RX-API-DMAC10.html)
EP (1) EP2968274B1 (cg-RX-API-DMAC10.html)
JP (2) JP2016517435A (cg-RX-API-DMAC10.html)
AU (2) AU2014227737B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015023621A8 (cg-RX-API-DMAC10.html)
CA (1) CA2906689A1 (cg-RX-API-DMAC10.html)
HK (1) HK1219233A1 (cg-RX-API-DMAC10.html)
WO (1) WO2014144285A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111362239B (zh) * 2020-03-20 2021-07-06 辽宁瑞鸥新材料科技有限公司 一种用于铝硅系合金半固态制浆的Cs2HPO4气溶胶及其使用方法
CN112076161B (zh) * 2020-08-07 2022-10-18 安徽康正康仁药业有限公司 一种头孢菌素类钠盐与丙磺舒钠组成的复方冻干制剂
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
CA3216616A1 (en) * 2021-04-27 2022-11-03 Philip V. Felice Compositions comprising cocrystals of acetylsalicylic acid and theanine with tromethamine and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA84584B (en) * 1983-01-28 1984-09-26 Bristol Myers Co Substituted vinyl cephalosporins
DE3475065D1 (en) * 1983-06-23 1988-12-15 Merck & Co Inc (acyloxyalkoxy) carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs, their preparation and pharmaceutical compositions containing said derivatives
US4914091A (en) * 1984-04-02 1990-04-03 American Cyanamid Company Esters of cephalosporin derivitives
JPS6247874A (ja) 1985-08-27 1987-03-02 Sankyo Seiki Mfg Co Ltd プログラム動作装置の初期化方法
GB9202298D0 (en) 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
JPH06192273A (ja) * 1992-10-26 1994-07-12 Lederle Japan Ltd カルバペネム−３−カルボン酸エステル誘導体
AU3649697A (en) * 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
JP2000344773A (ja) * 1998-07-17 2000-12-12 Kyoto Pharmaceutical Industries Ltd カルバペネム誘導体、およびその用途並びにその中間体化合物
JP2000344772A (ja) 1998-05-01 2000-12-12 Kyoto Pharmaceutical Industries Ltd カルバペネム誘導体、その用途およびその中間体化合物
SK16382000A3 (sk) 1998-05-01 2001-05-10 Kyoto Pharmaceutical Industries, Ltd. Karbapénové deriváty, ich vyžitie a ich medziproduktové zlúčeniny
JP2000344774A (ja) * 1999-06-03 2000-12-12 Meiji Seika Kaisha Ltd カルバペネム類の製造法
YU92003A (sh) * 2001-05-21 2006-05-25 Kyoto Pharmaceutical Industries Ltd. Karbapenem jedinjenje
US20050065141A1 (en) 2003-07-31 2005-03-24 Odink Debra A. Carbapenems useful in treating and preventing pulmonary infections, pharmaceutical compositions thereof and modes of administration thereof
EP2085084A1 (en) * 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics
BR112013009531A2 (pt) * 2010-11-11 2016-07-19 Redx Pharma Ltd derivados de fármaco
WO2013088255A1 (en) * 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
CN111700878A (zh) 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子

Also Published As

Publication number Publication date
JP2019089829A (ja) 2019-06-13
EP2968274B1 (en) 2019-10-16
US20160039823A1 (en) 2016-02-11
AU2014227737B2 (en) 2018-05-17
AU2014227737A1 (en) 2015-10-08
AU2018203005A1 (en) 2018-05-17
US20210332048A1 (en) 2021-10-28
JP6738918B2 (ja) 2020-08-12
WO2014144285A1 (en) 2014-09-18
EP2968274A4 (en) 2016-08-24
JP2016517435A (ja) 2016-06-16
BR112015023621A8 (pt) 2018-01-23
EP2968274A1 (en) 2016-01-20
CA2906689A1 (en) 2014-09-18
US10392388B2 (en) 2019-08-27
BR112015023621A2 (pt) 2017-07-18
US20200010470A1 (en) 2020-01-09
US11091487B2 (en) 2021-08-17
US9725451B2 (en) 2017-08-08
US20170349590A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
PH12018500147A1 (en) Benzodiazepine derivatives as rsv inhibitors
IN2014MN02106A (cg-RX-API-DMAC10.html)
WO2017123884A8 (en) Heterocyclic compounds as rsv inhibitors
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
JO3781B1 (ar) مشتقات الكينولون
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12018550120B1 (en) Steroid derivative fxr agonist
WO2013188792A3 (en) Neuroactive steroids, compositions, and uses thereof
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
UA112296C2 (uk) Сухий порошковий препарат, який містить інгібітор фосфодіестерази
IN2014DN09352A (cg-RX-API-DMAC10.html)
WO2011158042A3 (en) Ureido- pyrazole derivatives for use in the treatment of rhinovirus infections
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
TN2014000180A1 (en) Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
MX2015010829A (es) Compuestos terapeuticos y sus usos.
HK1217092A1 (zh) 治疗性化合物及其用途
HK1206021A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
PH12016500885A1 (en) Novel heterocyclic compounds
EA201491671A1 (ru) Гетероциклильные соединения
EA201590021A1 (ru) Новые замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса
EP4582424A3 (en) 1,2-naphthoquinone derivative and method for preparing same
PH12016500394A1 (en) Polymorphic form of pyrrole derivative and intermediate thereof
WO2014036502A3 (en) Tetracycline compounds
PH12016500980A1 (en) Amide derivatives for gpr119 agonist